The Primary Immunodeficiency or Primary Immune Deficiency Disease (PIDD) accounts for approximately 60% of Ig used for immunology patients and the growth of utilization year over year has been significant.
Highlights of our analysis demonstrate increasing annual dosage, prescriber variation and a steady increase in new and chronic patients, particularly in the sixth and seventh decade of life.
In 2016 the PIDD Working Group was formed in order to help establish a provincial framework for Ig use in PIDD. The Working Group representatives include: Dr. Doug Morrison (co-chair), Dr. Karen Dallas (co-chair), Dr. Bob Schellenberg, Dr. Donald Stark, Dr. Hein Reeves, Dr. Peter Lee, Dr. Kingsley Lee , Dr. Seung Kim, and Dr. Kyla Hildebrand.
The Working Group participated in the development of the Diagnostic and Treatment Algorithms as well as the PIDD Toolkit App.
| Algorithms | Dated |
| May 2018 | |
| May 2018 |
If you have questions or would like to learn more, please contact PBCO
